When, if ever, would you recommend risk reducing BSO in patients with moderate penetrance breast cancer germline mutations?
Genes such as ATM, CHEK2, PALB2, RAD51C/D, BRIP1 seem to show some potential increased risk of ovarian cancer. Should these patients under prophylactic oopherectomy or screening?
See JCO OGR 8/2021 by @Dr. First Last discussing management of non-BRCA pathogenic variants, and companion study (Kraft et al, 8/2021) evaluating the role of further characterization of polygenic risk score.
2 Answers
Mednet Member
Medical Oncology · Memorial Sloan Kettering Cancer Center
Answered on
RAD51C, RAD51D, and BRIP1 are all associated with significant risks of ovarian cancer and are appropriate for consideration of prophylactic oophorectomy, albeit perhaps at a slightly later age than BRCA1 and BRCA2. ATM and PALB2 may be associated with ovarian cancer risks that are similar to that of...
Join for free or sign in to see the full answer
Mednet Member
Medical Oncology · Indiana University School of Medicine
Answered on
While the risk of ovarian cancer with those mutations is not as high as for BRCA1, there does seem to be some risk. We also need to remember that RR BSO prior to menopause also reduces the risk of breast cancer. I would consider RR BSO in those patients whenever they have completed childbearing, max...
Join for free or sign in to see the full answer